HUP0303621A2 - Hasmenéscsökkentő ágenst és epotilont vagy epotilonszármazékot tartalmazó kombinációkat tartalmazó gyógyszerkészítmények - Google Patents

Hasmenéscsökkentő ágenst és epotilont vagy epotilonszármazékot tartalmazó kombinációkat tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0303621A2
HUP0303621A2 HU0303621A HUP0303621A HUP0303621A2 HU P0303621 A2 HUP0303621 A2 HU P0303621A2 HU 0303621 A HU0303621 A HU 0303621A HU P0303621 A HUP0303621 A HU P0303621A HU P0303621 A2 HUP0303621 A2 HU P0303621A2
Authority
HU
Hungary
Prior art keywords
epothilone
containing combinations
pharmaceutical compositions
compositions containing
antidiarrheal agent
Prior art date
Application number
HU0303621A
Other languages
English (en)
Inventor
Tianling Chen
Diane Greeley
John David Rothermel
Horst F. Schran
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0303621A2 publication Critical patent/HUP0303621A2/hu
Publication of HUP0303621A3 publication Critical patent/HUP0303621A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány tárgya a hatóanyagokat egyszerre, elválasztva vagy egymástkövetően alkalmazó kombináció, mely áll (a) egy hasmenéscsökkentőszerből és (b) egy (I) általános képletű - ahol <A< jelentéseoxigénatom vagy NRN általános képletű csoport, melyen belül RNjelentése hidrogénatom vagy rövid szénláncú alkilcsoport; R jelentésehidrogénatom vagy rövid szénláncú alkilcsoport; Z jelentése oxigénatomvagy kötés - epotilonszármazékból, mely (a) és (b) komponens lehetszabad állapotban vagy gyógyászati szempontból alkalmazható sóalakjában, adott esetben legalább egy gyógyászati szempontbólalkalmazható vivőanyag kíséretében. A hasmenéscsökkentő hatóanyaglehet például e DPP-IV gátló.A találmány kiterjed a kombinációkattartalmazó gyógyszerkészítményekre is. Ó
HU0303621A 2001-03-19 2002-03-18 Pharmaceutical compositions containing combinations comprising an antidiarrheal agent and epothilone or an epothilone HUP0303621A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27715301P 2001-03-19 2001-03-19
US27720701P 2001-03-20 2001-03-20
PCT/EP2002/002977 WO2002074042A2 (en) 2001-03-19 2002-03-18 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative

Publications (2)

Publication Number Publication Date
HUP0303621A2 true HUP0303621A2 (hu) 2004-03-01
HUP0303621A3 HUP0303621A3 (en) 2005-03-29

Family

ID=26958333

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303621A HUP0303621A3 (en) 2001-03-19 2002-03-18 Pharmaceutical compositions containing combinations comprising an antidiarrheal agent and epothilone or an epothilone

Country Status (27)

Country Link
US (1) US7030147B2 (hu)
EP (1) EP1372650B1 (hu)
JP (2) JP2004519493A (hu)
KR (1) KR100863089B1 (hu)
CN (1) CN100540001C (hu)
AT (1) ATE414514T1 (hu)
AU (1) AU2002251067B2 (hu)
BR (1) BR0208142A (hu)
CA (1) CA2440111C (hu)
CY (1) CY1108845T1 (hu)
CZ (1) CZ302848B6 (hu)
DE (1) DE60229922D1 (hu)
DK (1) DK1372650T3 (hu)
ES (1) ES2318001T3 (hu)
HK (1) HK1061516A1 (hu)
HU (1) HUP0303621A3 (hu)
IL (1) IL157333A0 (hu)
MX (1) MXPA03008462A (hu)
NO (1) NO333106B1 (hu)
NZ (1) NZ541703A (hu)
PT (1) PT1372650E (hu)
RU (1) RU2330661C2 (hu)
SI (1) SI1372650T1 (hu)
SK (1) SK287334B6 (hu)
TW (1) TWI331525B (hu)
WO (1) WO2002074042A2 (hu)
ZA (1) ZA200306318B (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US7018981B2 (en) * 2000-08-24 2006-03-28 Chugai Seiyaku Kabushiki Kaisha Cyclic motilin receptor antagonists
CZ305799B6 (cs) 2001-03-14 2016-03-23 Bristol-Myers Squibb Company Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
US6727261B2 (en) * 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE60330407D1 (de) 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
CA2518465A1 (en) * 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7723344B2 (en) * 2003-08-13 2010-05-25 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EP1699777B1 (en) * 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007513058A (ja) * 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GEP20094679B (en) 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
RU2253440C1 (ru) * 2004-03-31 2005-06-10 Открытое Акционерное Общество "Фаберлик" Средство для устранения нарушений нейрогенной и эндокринной регуляции системы капиллярного кровотока
JP2008501714A (ja) * 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP2805953B1 (en) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2597647A1 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
EP1931350B2 (en) * 2005-09-14 2021-08-04 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
RU2010123028A (ru) * 2007-11-09 2011-12-20 Новартис АГ (CH) Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
KR101478925B1 (ko) * 2013-12-31 2015-01-08 아주대학교산학협력단 프로테아좀 저해제와 로페라마이드를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
EP0932399B1 (en) * 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6103487A (en) * 1997-08-27 2000-08-15 Merck & Co., Inc. Method of treating cancer
US6127390A (en) * 1997-10-02 2000-10-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
PT1052974E (pt) * 1998-02-05 2009-08-07 Novartis Ag Formulação farmacêutica contendo epotilona
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
RU2003130058A (ru) 2005-04-10
ES2318001T3 (es) 2009-05-01
WO2002074042A2 (en) 2002-09-26
NO20034094D0 (no) 2003-09-15
KR20040025907A (ko) 2004-03-26
SK11702003A3 (sk) 2004-02-03
AU2002251067B2 (en) 2005-05-26
MXPA03008462A (es) 2003-12-08
BR0208142A (pt) 2004-03-02
HK1061516A1 (en) 2004-09-24
IL157333A0 (en) 2004-02-19
EP1372650B1 (en) 2008-11-19
CA2440111C (en) 2010-12-07
SI1372650T1 (sl) 2009-04-30
SK287334B6 (sk) 2010-07-07
RU2330661C2 (ru) 2008-08-10
WO2002074042A3 (en) 2003-02-27
US7030147B2 (en) 2006-04-18
JP2004519493A (ja) 2004-07-02
KR100863089B1 (ko) 2008-10-13
TWI331525B (en) 2010-10-11
CN1622805A (zh) 2005-06-01
EP1372650A2 (en) 2004-01-02
CN100540001C (zh) 2009-09-16
JP2010006830A (ja) 2010-01-14
DK1372650T3 (da) 2009-03-16
ATE414514T1 (de) 2008-12-15
CY1108845T1 (el) 2014-07-02
CZ302848B6 (cs) 2011-12-14
NZ541703A (en) 2007-04-27
US20040092478A1 (en) 2004-05-13
NO333106B1 (no) 2013-03-04
CA2440111A1 (en) 2002-09-26
ZA200306318B (en) 2005-02-23
CZ20032529A3 (cs) 2004-09-15
HUP0303621A3 (en) 2005-03-29
DE60229922D1 (de) 2009-01-02
PT1372650E (pt) 2009-02-25
PL363427A1 (en) 2004-11-15
NO20034094L (no) 2003-09-15

Similar Documents

Publication Publication Date Title
HUP0303621A2 (hu) Hasmenéscsökkentő ágenst és epotilont vagy epotilonszármazékot tartalmazó kombinációkat tartalmazó gyógyszerkészítmények
DE60112609D1 (en) Pyrazolopyridine
HUP0102160A2 (hu) Alfa-keto-enamin-származékok alkalmazása alkotórészként
HUP0203520A2 (hu) Bisz-acil-amidokat tartalmazó szilárd kozmetikai vagy gyógyszerészeti készítmény
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
SE0202483D0 (sv) Chemical compounds
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
TR200200778T2 (tr) Pirazol türevleri.
DE60108236D1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
BR0211427A (pt) Compostos, processo para preparar os mesmos, composição adequada para combater fungos danosos, uso de compostos, e, processo para combater fungos danosos
HK1048990A1 (en) Novel compounds.
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2002048148A3 (en) Pyrazolopyridine derivatives
HUP0402077A2 (hu) Fungicid hatóanyag-kombinációk
NO20065030L (no) Aerosolformulering for inhalering av beta agonister.
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
AU2003294092A1 (en) Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics
AU1366802A (en) 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives
AU2002248531A1 (en) Pyrazolopyriadine derivatives
HUP0402124A2 (hu) Pszichofarmakológiában alkalmazható pirazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
SE9904128D0 (sv) Novel compounds
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees